Immunotherapy Drug Extends Survival Rate Of Head And Neck Cancer Patients With Fewer Side Effects

Head and neck cancer patients who had received the immunotherapy drug nivolumab survived longer than those who received chemotherapy. They also experienced fewer side effects.